X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
female (28) 28
oncology (24) 24
middle aged (23) 23
index medicus (22) 22
adult (21) 21
aged (21) 21
breast cancer (19) 19
chemotherapy (14) 14
disease-free survival (12) 12
life sciences (12) 12
male (11) 11
breast neoplasms - drug therapy (10) 10
cancer (10) 10
aged, 80 and over (9) 9
immunology (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
breast neoplasms - pathology (8) 8
hematology, oncology and palliative medicine (8) 8
trastuzumab (8) 8
treatment outcome (8) 8
antibodies, monoclonal, humanized - administration & dosage (7) 7
therapy (7) 7
tumors (7) 7
[ sdv.imm ] life sciences [q-bio]/immunology (6) 6
antineoplastic agents (6) 6
antineoplastic agents - therapeutic use (6) 6
cisplatin (6) 6
drug administration schedule (6) 6
neoplasm metastasis (6) 6
prognosis (6) 6
research (6) 6
survival (6) 6
antibodies, monoclonal, humanized - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
bevacizumab (5) 5
breast neoplasms - mortality (5) 5
capecitabine (5) 5
drug therapy (5) 5
follow-up (5) 5
medicine & public health (5) 5
metastasis (5) 5
neoplasm staging (5) 5
paclitaxel (5) 5
product development (5) 5
receptor, erbb-2 - analysis (5) 5
studies (5) 5
survival analysis (5) 5
trial (5) 5
[sdv.imm]life sciences [q-bio]/immunology (4) 4
antimitotic agents (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic agents - pharmacokinetics (4) 4
breast neoplasms - chemistry (4) 4
breast neoplasms - genetics (4) 4
care and treatment (4) 4
chemotherapy, adjuvant (4) 4
cisplatin - administration & dosage (4) 4
clinical trials (4) 4
combination (4) 4
kaplan-meier estimate (4) 4
mesh : female (4) 4
mesh : humans (4) 4
metastatic breast cancer (4) 4
neoplasm recurrence, local - drug therapy (4) 4
quality of life (4) 4
taxoids - administration & dosage (4) 4
young adult (4) 4
[ sdv ] life sciences [q-bio] (3) 3
anthracyclines (3) 3
breast neoplasms - surgery (3) 3
cancer research (3) 3
cancer therapies (3) 3
cisplatin - pharmacokinetics (3) 3
docetaxel (3) 3
dosage and administration (3) 3
genetic aspects (3) 3
genomes (3) 3
health aspects (3) 3
injections, intraperitoneal (3) 3
internal medicine (3) 3
mesh : adult (3) 3
mesh : aged (3) 3
mesh : cisplatin (3) 3
mesh : injections, intraperitoneal (3) 3
mesh : middle aged (3) 3
mesh : ovarian neoplasms (3) 3
mesh: adult (3) 3
mesh: aged (3) 3
mesh: female (3) 3
mesh: humans (3) 3
mesh: middle aged (3) 3
mesh: models, biological (3) 3
models, biological (3) 3
mutation (3) 3
neoplasm recurrence, local - pathology (3) 3
ovarian cancer (3) 3
ovarian neoplasms (3) 3
ovarian neoplasms - drug therapy (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 933 - 942
Journal Article
by Pivot, Xavier and Romieu, Gilles and Debled, Marc and Pierga, Jean-Yves and Kerbrat, Pierre and Bachelot, Thomas and Lortholary, Alain and Espié, Marc and Fumoleau, Pierre and Serin, Daniel and Jacquin, Jean-Philippe and Jouannaud, Christelle and Rios, Maria and Abadie-Lacourtoisie, Sophie and Venat-Bouvet, Laurence and Cany, Laurent and Catala, Stéphanie and Khayat, David and Gambotti, Laetitia and Pauporté, Iris and Faure-Mercier, Celine and Paget-Bailly, Sophie and Henriques, Julie and Grouin, Jean Marie and Piprot, C and Cals, L and Chaigneau, L and Demarchi, F and N'Guyen, T and Stein, U and Villanueva, C and Bréau, JL and Chouahnia, AK and Saintigny, P and Boué, F and deSaint-Hilaire, P and Guimont, I and Grossat, N and Valenza, B and Lévy, E and Médioni, J and Delbaldo, C and Grenier, J and Pouessel, D and Lavau-Denès, S and Falandry, C and Fournel-Fédérico, C and Freyer, G and Tartas, S and Trillet-Lenoir, V and Bons, F and Auclerc, G and Chièze, S and Raban, N and Tournigand, C and Trager-Maury, S and Bousquet, G and Cuvier, C and Giacchetti, S and Hocini, A and LeMaignan, C and Misset, JL and Avenin, D and Beerblock, C and Gligorov, J and Rivera, P and Roché, H and Bougnoux, P and Hajjaji, N and Capitain, O and Delva, R and Maillart, P and Soulié, P and Bonnefoi, H and Durand, M and Madranges, N and Mauriac, L and Chollet, P and Dillies, AF and Durando, X and Ferrière, JP and Mouret-Reynier, C and Nabholtz, JM and Van Praagh, I and Cottu, P and Diéras, V and Durieux, A and Galotte, M and Girre, V and Henry, S and Iurisci, I and Jouve, M and Laurence, V and Mignot, L and Piperno-Neumann, S and Tresca, P and Coudert, B and Ferrant, E and Mayer, F and Vanneuville, AC and ... and PHARE Trial Investigators and PHARE trial investigators
The Lancet, ISSN 0140-6736, 06/2019, Volume 393, Issue 10191, pp. 2591 - 2598
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 741 - 748
Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer.... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | FOLLOW-UP | CHEMOTHERAPY | Breast Neoplasms - surgery | Predictive Value of Tests | Breast Neoplasms - secondary | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasms, Second Primary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | France | Heart Diseases - chemically induced | Radiotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Early Detection of Cancer | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Antineoplastic agents | Cancer
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 357 - 366
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2015, Volume 2, Issue 1, pp. e37 - e46
Journal Article
by Hudson, Thomas J and Anderson, Warwick and Aretz, Axel and Barker, Anna D and Bell, Cindy and Bernabé, Rosa R and Bhan, M. K and Calvo, Fabien and Eerola, Iiro and Gerhard, Daniela S and Guttmacher, Alan and Guyer, Mark and Hemsley, Fiona M and Jennings, Jennifer L and Kerr, David and Klatt, Peter and Kolar, Patrik and Kusuda, Jun and Lane, David P and Laplace, Frank and Lu, Youyong and Nettekoven, Gerd and Ozenberger, Brad and Peterson, Jane and Rao, T. S and Remacle, Jacques and Schafer, Alan J and Shibata, Tatsuhiro and Stratton, Michael R and Vockley, Joseph G and Watanabe, Koichi and Yang, Huanming and Yuen, Matthew M. F and Knoppers, Bartha M and Bobrow, Martin and Cambon-Thomsen, Anne and ssler, Lynn G and Dyke, Stephanie O. M and Joly, Yann and Kato, Kazuto and Kennedy, Karen L and Nicolás, Pilar and Parker, Michael J and Rial-Sebbag, Emmanuelle and Romeo-Casabona, Carlos M and Shaw, Kenna M and Wallace, Susan and Wiesner, Georgia L and Zeps, Nikolajs and Lichter, Peter and Biankin, Anew V and Chabannon, Christian and Chin, Lynda and Clément, Bruno and de Alava, Enrique and Degos, Françoise and Ferguson, Martin L and Geary, Peter and Hayes, D. Neil and Johns, Amber L and Kasprzyk, Arek and Nakagawa, Hidewaki and Penny, Robert and Piris, Miguel A and Sarin, Rajiv and Scarpa, Aldo and van de Vijver, Marc and Futreal, P. Anew and Aburatani, Hiroyuki and Bayés, Mónica and Bowtell, David D. L and Campbell, Peter J and Estivill, Xavier and Grimmond, Sean M and Gut, Ivo and Hirst, Martin and López-Otín, Carlos and Majumder, Partha and Marra, Marco and McPherson, John D and Ning, Zemin and Puente, Xose S and Ruan, Yijun and Stunnenberg, Henik G and Swerdlow, Harold and Velculescu, Victor E and Wilson, Richard K and Xue, Hong H and Yang, Liu and Spellman, Paul T and Bader, Gary D and Boutros, Paul C and Flicek, Paul and Getz, Gad and Guigó, Roderic and Guo, Guangwu and Haussler, David and Heath, Simon and Hubbard, Tim J and Jiang, Tao and ... and Int Canc Genome Consortium and International Cancer Genome Consortium and The International Cancer Genome Consortium and Science for Life Laboratory, SciLifeLab and Centra and Proteomik (stängd 20130101) and Skolan för bioteknologi (BIO) and KTH
Nature, ISSN 0028-0836, 2010, Volume 464, Issue 7291, pp. 993 - 998
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 656 - 666
Journal Article